MS
KPTI icon

Maven Securities’s Karyopharm Therapeutics KPTI Stock Holding History

Maven Securities’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,462
Closed -$572K – 1234
2020
Q4 		$572K Buy
+2,462
New +$570K 0.06% 330

Other funds holding KPTI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
DMPV
Delphi Management Partners VIII San Mateo, California $138M AUM 56.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Maven Securities's KPTI Position: Q1 2021 in Review

Maven Securities sold out of Karyopharm Therapeutics (KPTI) in Q1 2021, closing a stake of 2,462 shares — an estimated $572K sold.

Maven Securities first reported a position in KPTI in Q4 2020 and held it in 1 quarter. The position peaked at $572K in Q4 2020. 171 funds tracked by Wall St. Rank hold KPTI as of Q1 2021.

  • Maven Securities reported no remaining Karyopharm Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Maven Securities sold 2,462 Karyopharm Therapeutics shares in Q1 2021, an estimated $572K.
  • Maven Securities first reported a position in Karyopharm Therapeutics in Q4 2020 and held it in 1 quarter.
  • Maven Securities's Karyopharm Therapeutics position peaked at $572K in Q4 2020.
  • 171 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2021.

Based on Maven Securities's 13F filing for Q1 2021, filed 17 May 2021.